Tag: Affera
Abbott, Medtronic announce positive data on respective PFA systems at HRS...
Among a great number of presentations relating to pulsed field ablation (PFA) treatments for atrial fibrillation (AF) at this year’s Heart Rhythm Society (HRS)...
European registry elucidates safety outcomes of ventricular arrhythmia treatment with Affera...
A novel cardiac ablation system may hold the potential to improve upon the currently available treatments for ventricular arrhythmia (VA) patients, having demonstrated positive...
Medtronic announces first patient enrolment in trial assessing VT treatment with...
Medtronic recently announced that the first patient has been enrolled in a US Food and Drug Administration (FDA) early feasibility study evaluating the Affera...
Texas Cardiac Arrhythmia Institute becomes first in USA to use FDA-approved...
Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St David's Medical Center (Austin, USA) recently became the first in the USA to use...
Medtronic receives US FDA approval of Affera mapping and ablation system...
Medtronic has announced US Food and Drug Administration (FDA) approval of the Affera mapping and ablation system with Sphere-9 catheter, an all-in-one, high-density (HD)...
Medtronic adds cardiac mapping platform through Affera acquisition
Medtronic has announced that it has completed the acquisition of Affera. The acquisition will expand Medtronic’s cardiac ablation portfolio to include its first cardiac...
Medtronic to acquire Affera
Medtronic has announced that it has entered into an agreement to acquire medical technology company Affera.
Affera designs and manufactures cardiac mapping and navigation systems...